i3 Expands Partnership With Eli Lilly and Company
Pharmaceutical services company i3 announced that global pharmaceutical firm Eli Lilly and Company (NYSE: LLY) is transferring select activities to support its U.S. clinical trials, including the areas of U.S. medical writing and biostatistical services, to i3 as part of Lilly’s continuing effort to transform its business in order to speed improved outcomes to individual patients. This move marks a significant expansion of the business relationship between the two organizations since Lilly transferred the majority of its U.S. data management operations to i3 in 2008.
This agreement builds on i3’s steady growth in the area of functional service provision (FSP), having composed and deployed successful FSP teams throughout the industry since 1999.
Life science companies have found that partnering with service providers in functional areas, such as information sciences—including data management, medical writing, and biostatistical services—enhances efficiencies, improves quality, and reduces costs.
“i3, with an established presence on the north side of Indianapolis, has proved itself as a partner capable of consistently delivering high-quality work within our agreed-upon performance metrics,” said Aarti Shah, Ph.D., vice president statistics and advanced analytics hub, Eli Lilly and Company.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
